The government analyst attached to the drugs testing laboratory has warned against the use of a range of drug formulations that are not of standard quality during their mandatory testing of products.

According to a communiqué from the drugs control department, Onida Pharmaceuticals, Gaziabad, near New Delhi which manufactured Nimusil-Plus, Nimesulide and paracetomal tablets Batch No, BT 065 was found not to comply with the standard quality.

The second drug was dexamethasone sodium phosphate injection IP Batch No. 36 of Hindustan Pharmaceutical, Barauni. The third drug was Serax tablets M23013, Mars Therapeutics and Chemicals, Secunderabd. The fourth included enterobact norflaxacin and tiniclazole tablets, UAN 4018 A, Anstrin Pharma, Ghatkopar, Mumbai. The fifth drug found to be not of standard quality was erythromycin sterate tablets IP 1824 of the Hindustan Antibiotics Pimpri Pune.

The drug test lab in Karnataka drugs control department has also found doxycycline capsules IP 039V British Pharmaceuticals, Mumbai, amoxycilline capsules NGL 23, Bengal Immunity Limited, Kolkata and amocycline capsules 145 P of British Pharmaceuticals that were among the medicines identified by the analysts which are not of standard quality.

The analysts also warned chemists, wholesalers, doctors, hospitals and nursing homes against stocking, selling and using these drugs.